TFB Advisors LLC Has $213,000 Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

TFB Advisors LLC lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 22.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,479 shares of the company’s stock after selling 709 shares during the period. TFB Advisors LLC’s holdings in Novo Nordisk A/S were worth $213,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the stock. Beacon Financial Group boosted its holdings in shares of Novo Nordisk A/S by 7.8% during the 4th quarter. Beacon Financial Group now owns 2,707 shares of the company’s stock valued at $233,000 after acquiring an additional 195 shares in the last quarter. Warther Private Wealth LLC raised its position in Novo Nordisk A/S by 14.2% in the fourth quarter. Warther Private Wealth LLC now owns 12,021 shares of the company’s stock valued at $1,034,000 after purchasing an additional 1,497 shares during the last quarter. Leavell Investment Management Inc. boosted its stake in shares of Novo Nordisk A/S by 13.6% during the fourth quarter. Leavell Investment Management Inc. now owns 3,968 shares of the company’s stock valued at $341,000 after purchasing an additional 475 shares in the last quarter. Portfolio Design Labs LLC bought a new stake in shares of Novo Nordisk A/S during the fourth quarter worth about $208,000. Finally, Augustine Asset Management Inc. acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $1,693,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $81.78 on Thursday. The company has a market cap of $366.99 billion, a P/E ratio of 24.86, a PEG ratio of 0.96 and a beta of 0.45. The company has a current ratio of 0.74, a quick ratio of 0.75 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average price of $90.45 and a two-hundred day moving average price of $110.60. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 21.88%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday. They set an “equal weight” rating for the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.